CD44 and ovarian neoplasm: Furthermore, given that the FDA has recently approved the anti-CD44 antibody drug conjugate (ADC) treatment for HGSC, the increased CD44 expression observed in the tumoroids reinforces the utility of this targeted therapy and suggests that the anti-CD44 antibody could reduce the presence of cancer stem-like cells promoted by MSC and macrophages in the ovarian tumor microenvironments.[60]